Navigation Links
Central in Medical Technology

Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

... unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and ... the Benelux countries, and Poland for Eastern and central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology. ...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

... unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and ... the Benelux countries, and Poland for Eastern and central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology. ...

Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion

... the treatment of certain eye diseases, to include central Retinal Vein Occlusion (CRVO). The companies plan ... this year. CRVO is caused by obstruction of the central retinal vein that that leads to a back up of ... from CRVO. CRVO is caused by obstruction of the central retinal vein that leads to a back up of blood and ...

Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder

... unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and ... the Benelux countries, and Poland for Eastern and central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology. ...

Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression

... unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and ... the Benelux countries, and Poland for Eastern and central European countries. Cephalon Europe markets more than 30 products in four areas: central nervous system, pain, primary care and oncology. ...

10-State Project to Study Methods to Reduce Central Line-Associated Bloodstream Infections in Hospital ICUs

... to help prevent infections related to the use of central line catheters. central venous catheters or central line catheters are tubes placed into a large vein ...

Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection

... use: increased risk of complications from using central catheters, such as infections or breaks in the ... has been to supply antibiotics through a central venous catheter over a four- to six-week period ... IV therapy had complications related to the central venous catheter." Zaoutis's study found wide ...

FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A

... The most common adverse events were related to central venous access, such as catheterization and catheter removal, central line infection and pyrexia. The study was ... including countries in Asia and South and central America, where the product is approved based on ...

Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)

... focused on the treatment of obesity and other central nervous system-related disorders, today ... focused on the treatment of obesity and other central nervous system-related disorders. The Company's ... to act on a specific group of neurons in the central nervous system with the goal of achieving ...

Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer

... (PFS) assessed via a blinded, independent central review and defined as the amount of time between ... groups (2% vs. 0% of responders). However, in a central review among patients evaluable for best ... metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and ...

Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule

... Food and Drug Administration (FDA) to treat other central nervous system disorders. Orexigen has developed ... product candidates for the treatment of central nervous system disorders, including obesity. The ... other proprietary drugs for use in other central nervous system disorders. Further information ...

Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments

... by continuously inhibiting the mTOR protein, a central regulator of tumor cell division and blood vessel ... RAD001 inhibits mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism ... metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and ...

New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk

... kidney disease. SphygmoCor(R) is a non-invasive central blood pressure assessment technology that has ... in the "high normal" range (130-139 mm Hg) had central systolic blood pressures corresponding to those ... "The real significance of these findings is that central and brachial blood pressures are not the same, ...

BARC Announces Long-Term Cooperation In South African Biobanking for HIV Vaccine Trials

... in South Africa as the key provider of global central lab services for clinical trials." Rudi Marien, ... + 329 329 2 327 BARC is an independent global central laboratory, with subsidiaries in USA, Europe, ... clinical trials. BARC is committed to providing central laboratory services, including biobanking, that ...

RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer

... (PFS) assessed via a blinded, independent central review and defined as the amount of time between ... groups (1% vs. 0% of responders). However, in a central review among patients evaluable for ... RAD001 inhibits mTOR, a protein that acts as a central regulator of tumor cell division, ...

RICE MEMORIAL HOSPITAL PHARMACY STAFF EXPERIENCES A 55% REDUCTION IN TIME SPENT MANAGING PATIENT-SPECIFIC MEDICATIONS USING OMNICELL SINGLEPOINTE SOLUTION

... Hospital, a major healthcare facility in West central Minnesota, today announced results from a ... range from complete automation systems for the central pharmacy to nursing unit and bedside dispensing ... facility that encompasses 14 counties in west central Minnesota and is licensed for 136 beds to provide ...

FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment

... reaches the brain and S1P-Rs are present on central nervous system (CNS) tissue, so FTY720 may have a ... metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and ... 8425 Isabella Zinck +41 61 324 7188 central phone no: +41 61 324 7944 Fax no: ...

Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital

... disease) breathe more easily. central DuPage Hospital is the only site for the EASE ... and principal investigator of the study at the central DuPage Hospital site. "Emphysema, ... visit http://www.theEASEtrial.com . About central DuPage Hospital ...

Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease

... to expand our pipeline of product candidates in central nervous system disorders," said Paul E. Freiman, ... Technologies and Buck focused on central nervous system conditions. "With these ... on developing novel, first-in-class agents for central nervous system conditions and other serious ...

Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy

... treatment by inhibiting the mTOR protein, a central regulator of tumor cell division and blood vessel ... inhibits mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism ... metabolic, cancer, organ transplantation, central nervous system, dermatological, gastrointestinal ...

Ellex 2RT Study Demonstrates Clinical Efficacy in Treatment of Diabetic Macular Edema

... experienced improvement in visual acuity and central macular thickness (CMT) as measured by optical coherence tomography. central macular thickness decreased in 55% of eyes and remained stable in 24%. An increase in central macular thickness was observed in only 20% of ...

Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord

... cord that often leads to stroke or death. Primary central nervous system vasculitis (PCNSV) can best be ... a combined diagnostic approach is needed. Primary central nervous system vasculitis is difficult to ... of the Mayo Clinic Research Primary central nervous system vasculitis has two traits that ...

Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease

... disease is a progressive disorder of the central nervous system. The patients -- roughly four ... a lack of dopamine, a messenger substance in the central nervous system, which is responsible for the ... and biotechnology products in the fields of central nervous system disorders, ...

Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting

... (GI) transit time without reversing the central opioid effect as measured by pupillometry. ... of morphine-induced pupil constriction, a central nervous system (CNS) effect. Escalating single ... while maintaining substantial central analgesic effect. In addition, ...

Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome

... occurrence of scoliosis. In patients with GHD, central (secondary) hypothyroidism may first become ... treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be ... fluid retention and unmasking of latent central hypothyroidism. Most serious adverse reactions ...

Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome

... occurrence of scoliosis. In patients with GHD, central (secondary) hypothyroidism may first become ... treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be ... fluid retention and unmasking of latent central hypothyroidism. Most serious adverse reactions ...

Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy

... Schedule Monday, September 17, 7:00 p.m. central Daylight Time, Room E354A -- Satellite ... Management Tuesday, September 18, 11:15 a.m. central Daylight Time, Room E253D Poster Session 222: ... Macaques Wednesday, September 19, 12:15 p.m. central Daylight Time, Hall D Poster Session 176: ...

Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain

... NTDDS projects are focused upon peripheral and central nervous system applications. To that end, ... ways using the synapse between the peripheral and central nervous systems. This synapse provides input from ... role not only in diabetes but also in several central nervous system-related diseases. Diamyd Medical ...

Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis

... (MS) is a chronic, progressive, often disabling disease that attacks the central nervous system(ii). MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central nervous system, resulting in disrupted nerve impulses traveling to and ...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

... platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced today results from the first ... identify novel pathways for small molecule therapeutics to treat various central nervous system (CNS) diseases. Neurogenesis is the process by which ...

First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center

... to bringing the most complete and innovative cancer care to patients in central Wisconsin, which is why we are so excited to introduce electronic ... in Madison, WI. In November 2006 the Riverview center became the first in central Wisconsin to treat patients with helical tomotherapy, the most ...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

... those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's ... media.relations@novartis.com Novartis Investor Relations central phone: +41 61 324 7944 Ruth Metzler-Arnold +41 61 324 9980 ...

Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints

... affects 0.5% - 5% of adults worldwide. Fibromyalgia is believed to be a central nervous system condition, resulting from neurological changes in how the ... development and commercialization of innovative medicines with a focus on central nervous system and immunology disorders. Employing around 10,000 people in ...

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

... developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced that it has obtained the rights to ... developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor ...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

... targets in peripheral tissues such as liver and fat without affecting the central nervous system, further validating Isis' anti-obesity therapeutic ... drugs could have significant therapeutic utility without the potential for central nervous system toxicities that plague many centrally acting anti-obesity ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... AEs resulted from infections, liver enzyme increases and fully reversible central nervous system events. "The observation of high response rate and ... call will be available from 1:00 pm Eastern Time on June 8, 2009 (7:00 pm central European Time) through June 15, 2009. The replay number is 888-286-8010 ....

Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions

... the BLOOM Trial," will be displayed from June 6, 2009 at 10:00 a.m. central Daylight Time (CDT) until June 8, 2009 at 4:00 p.m. CDT in the Morial ... oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced ...

Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimer's Treatments

... announced that it has developed a robust medical imaging methodology for central Nervous System (CNS) clinical trials involving Alzheimer's disease. The ... and services a wide range of therapeutic areas, including oncology, central nervous system, musculoskeletal, cardiovascular, and ...

Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications

... the delivery of diagnostic and therapeutic agents across the BBB into the central nervous system ("CNS"). The claims broadly encompass all neurological ... diagnostic and therapeutic agents across the blood-brain barrier into the central nervous system; that the allowed claims and patents, if issued, offer ...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

... progression-free survival, which was assessed via a blinded independent, central radiological review(10). About Afinitor Afinitor is the first ... cancer cells, Afinitor continuously targets mTOR, a protein that acts as a central regulator of tumor cell division, blood vessel growth and cell metabolism. ...
Other Contents
(Date:7/11/2014)... "mouse TRAP" to capture the early signs of kidney ... the Journal of Clinical Investigation . Their new ... extract cellular and genetic information from a variety of ... Institute for Medical Research in 2008, TRAP involves attaching ... of the cell type of interest. Scientists can then ...
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... division of the striatum is also involved in ... of substance P in the striatal marginal division ... his team, College of Biophotonics, South China Normal ... P receptor, neurokinin 1 was highly expressed in ... rats. Unilateral or bilateral injection of an antisense ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
(Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
(Date:7/13/2014)... July 13, 2014 The Pearland, Texas location ... in age from four months to 12 years of age ... classes to birthday parties and Summer Camps, is now under ... Gym of Pearland after spending over six years at ... including Gym Director. , Berry has over ten years ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... 2014 Fadhits.com is popular among worldwide ... are extremely beautiful. Recently, the company has announced its ... 2014. What’s more, all these outfits are available at ... , Additionally, the supplier is now offering similar discounts ... dresses, it has many other designs for sale, including ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
Other TagsOther Tags